ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Top Brokers

More Brokers

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
FTSE 100
8,275.38
0.54%
Dow Jones
38,686.32
1.51%
Gold vs US Dollar
2,327.355
0.00%
Brent Oil
81.295
0.00%
Bitcoin
67,814.59
0.13%
Pepperstone
Advertisement
Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. Pliant Therapeutics Inc (PLRX)

  7. Pliant Therapeutics Inc (PLRX) News

Pliant Therapeutics (PLRX)

Pliant Therapeutics Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:PLRX
DateTimeSourceHeadlineSymbolCompany
21/05/202423:50GlobeNewswire Inc.Pliant Therapeutics Presents Data from its Bexotegrast Program at the American Thoracic Society International ConferenceNASDAQ:PLRXPliant Therapeutics Inc
14/05/202412:43Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:PLRXPliant Therapeutics Inc
14/05/202412:30GlobeNewswire Inc.Pliant Therapeutics Announces Positive Topline Data from a Phase 2a Collagen PET Imaging Clinical Trial of Bexotegrast in Patients with Idiopathic Pulmonary FibrosisNASDAQ:PLRXPliant Therapeutics Inc
07/05/202413:00GlobeNewswire Inc.Pliant Therapeutics Announces Upcoming Presentations at the European Association for the Study of the Liver International Liver Congress™NASDAQ:PLRXPliant Therapeutics Inc
06/05/202421:27Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:PLRXPliant Therapeutics Inc
06/05/202421:11Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:PLRXPliant Therapeutics Inc
06/05/202421:05GlobeNewswire Inc.Pliant Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial ResultsNASDAQ:PLRXPliant Therapeutics Inc
06/05/202411:02Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:PLRXPliant Therapeutics Inc
01/05/202413:00GlobeNewswire Inc.Pliant Therapeutics to Participate in Upcoming Investor EventsNASDAQ:PLRXPliant Therapeutics Inc
02/04/202413:00GlobeNewswire Inc.Pliant Therapeutics to Participate in Upcoming Investor EventsNASDAQ:PLRXPliant Therapeutics Inc
27/03/202414:23GlobeNewswire Inc.Pliant Therapeutics Announces Upcoming Presentations at the 2024 American Thoracic Society International ConferenceNASDAQ:PLRXPliant Therapeutics Inc
12/03/202411:30GlobeNewswire Inc.Pliant Therapeutics Announces Accelerated Bexotegrast Development Plan for the Treatment of Idiopathic Pulmonary FibrosisNASDAQ:PLRXPliant Therapeutics Inc
27/02/202421:20Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:PLRXPliant Therapeutics Inc
27/02/202421:06Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:PLRXPliant Therapeutics Inc
27/02/202421:03GlobeNewswire Inc.Pliant Therapeutics Provides Corporate Update and Reports Fourth Quarter 2023 Financial ResultsNASDAQ:PLRXPliant Therapeutics Inc
26/02/202413:00GlobeNewswire Inc.Pliant Therapeutics to Participate in Upcoming Investor ConferencesNASDAQ:PLRXPliant Therapeutics Inc
15/02/202401:55Edgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:PLRXPliant Therapeutics Inc
14/02/202413:52Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:PLRXPliant Therapeutics Inc
07/02/202413:00GlobeNewswire Inc.Pliant Therapeutics to Participate in Upcoming Investor EventsNASDAQ:PLRXPliant Therapeutics Inc
05/02/202412:31Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:PLRXPliant Therapeutics Inc
04/02/202420:29GlobeNewswire Inc.Pliant Therapeutics Announces Positive Safety and Exploratory Efficacy Data from the INTEGRIS-PSC Phase 2a Trial of Bexotegrast 320 mg in Patients with Primary Sclerosing Cholangitis and Suspected Liver FibrosisNASDAQ:PLRXPliant Therapeutics Inc
24/01/202421:57Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:PLRXPliant Therapeutics Inc
24/01/202421:57Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:PLRXPliant Therapeutics Inc
24/01/202421:57Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:PLRXPliant Therapeutics Inc
24/01/202421:56Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:PLRXPliant Therapeutics Inc
19/01/202422:19Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:PLRXPliant Therapeutics Inc
19/01/202422:19Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:PLRXPliant Therapeutics Inc
19/01/202422:11Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:PLRXPliant Therapeutics Inc
03/01/202413:00GlobeNewswire Inc.Pliant Therapeutics to Participate in the 42nd Annual J.P. Morgan Healthcare ConferenceNASDAQ:PLRXPliant Therapeutics Inc
13/11/202321:30GlobeNewswire Inc.Pliant Therapeutics Presentations at The Liver Meeting® 2023 Highlight Bexotegrast, an Inhibitor of αvß6 and αvß1 Integrins, in Primary Sclerosing CholangitisNASDAQ:PLRXPliant Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:PLRX

Your Recent History

BIT
P21LI9
NLBNPIT21LI9 20241218 21...
TSX
ZDM
BMO MSCI EAFE Hedged to ...
TSX
BRAG
Bragg Gaming
Delayed Upgrade Clock
    ADVFN Logo
    InvestorsHub

    United Kingdom
    Company
    Business
    Popular
    Get The App
    App Store
    Google Play

    Support: +44 (0) 203 8794 460 | support@advfn.com

    By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

    © 2024 ADVFN PLC - All Rights Reserved